SCHEMBL7184875

SCHEMBL7184875

Cc1cc(C)c(C(=O)P(=O)(C(=O)c2c(Cl)c(Cl)c(Cl)c(Cl)c2Cl)c2ccccc2)c(C)c1C

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.33
TAAR1 Q96RJ0 1/20 0.32
TP53 P04637 2/20 0.32
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
NPC1 O15118 3/20 0.31
RAB9A P51151 1/20 0.31
MAPK1 P28482 2/20 0.30
APAF1 O14727 1/20 0.30
LMNA P02545 1/20 0.30
MAPT P10636 1/20 0.30
HPGD P15428 1/20 0.30
HTT P42858 1/20 0.30
MCL1 Q07820 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
POLB P06746 1/20 0.30
CA2 P00918 1/20 0.30
CA4 P22748 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7180941 0.92 TP53 (0.33) ALDH1A1TAAR1TP53MEN1KMT2A
SCHEMBL7181616 0.91 KMT2A (0.36) ALDH1A1TP53MEN1KMT2ANPC1
SCHEMBL7174855 0.88 GFER (0.35) ALDH1A1TP53MEN1KMT2ANPC1
SCHEMBL7180464 0.88 KMT2A (0.34) ALDH1A1TP53MEN1KMT2ANPC1
SCHEMBL7177492 0.88 NPC1 (0.33) ALDH1A1TAAR1TP53MEN1KMT2A
SCHEMBL7175604 0.88 MAPT (0.36) ALDH1A1TP53MEN1KMT2ARAB9A
SCHEMBL7183795 0.87 PTGS2 (0.34) ALDH1A1TP53MEN1KMT2ANPC1
SCHEMBL7182790 0.86 MAPT (0.35) ALDH1A1TP53MEN1KMT2ANPC1
SCHEMBL7177289 0.86 L3MBTL1 (0.34) ALDH1A1MEN1KMT2ANPC1RAB9A
SCHEMBL7180033 0.86 LMNA (0.35) ALDH1A1MEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 ALDH1A1 3416/4885TAAR1 1345/4885TP53 3575/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 ALDH1A1 3984/4885TAAR1 1464/4885TP53 3524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.